v3.26.1
Commitments and Contingencies (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
May 06, 2026
USD ($)
Mar. 01, 2026
USD ($)
Feb. 28, 2026
USD ($)
candidate
Dec. 31, 2025
USD ($)
asset
Oct. 31, 2025
USD ($)
May 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Aug. 31, 2025
USD ($)
Jul. 31, 2025
USD ($)
May 31, 2023
amendment
Commitments and Contingencies                            
Purchase obligation               $ 222,900            
Research and development               108,692 $ 44,172          
Prepaid expenses and other current assets       $ 47,804       64,955            
Number of office lease amendment | amendment                           4
Obtaining an operating lease right-of-use asset in exchange for an operating lease liability   $ 1,400       $ 4,000   1,672 $ 0 $ 1,300 $ 1,600      
Operating lease right-of-use assets       4,939       6,203            
Unrecorded unconditional purchase obligation, including lease not yet commenced, total               $ 9,900            
Lessee, operating lease, lease not yet commenced, term of contract               84 months            
Operating lease prepayment amount               $ 1,200            
Lessee, operating lease, term of contract (in days)   24 months                        
West Conshohocken, Pennsylvania                            
Commitments and Contingencies                            
Operating lease right-of-use assets               4,000            
Operating lease, liability               4,600            
Faroe License | Subsequent Event                            
Commitments and Contingencies                            
Upfront payment $ 25,000                          
Arrowhead License | Subsequent Event                            
Commitments and Contingencies                            
Collaborative arrangement, milestone payment, eligible to receive $ 975,000                          
Hoffmann-La Roche ("Roche") | Research, Development and Commercialization Agreement                            
Commitments and Contingencies                            
Milestone payment due             $ 5,000              
Remainder of future milestone payments                       $ 3,000    
CSPC                            
Commitments and Contingencies                            
Upfront payment         $ 120,000                  
Maximum of eligible milestone payments                         $ 2,000,000  
Pfizer                            
Commitments and Contingencies                            
Upfront payment       50,000                    
Maximum of eligible milestone payments       $ 70,000                    
Number of additional early stage MASH assets | asset       2                    
Suzhou Ribo Life Science Co. Ltd. And Ribocure Pharmaceuticals AB                            
Commitments and Contingencies                            
Upfront payment     $ 60,000                      
Maximum of eligible milestone payments     $ 4,400,000                      
Number of siRNA candidates | candidate     6                      
Research and development               48,300            
Prepaid expenses and other current assets               $ 11,700